Home » Promega Gets CE Mark for Solid Tumor Diagnostic
Promega Gets CE Mark for Solid Tumor Diagnostic
Wisconsin-based Promega has earned a CE mark for its OncoMate MSI Dx analysis system for detecting microsatellite instability (MSI) in solid tumors.
MSI biomarkers can be used to predict a patient’s response to immune-oncology therapies for certain cancers.
“Screening cancer patients with these reliable markers” can help guide care and treatment decisions, the company said.
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May